Breaking News, Collaborations & Alliances

Targacept Earns $20 Million AZ Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca (AZ) plans to continue development of AZD3480 (TC-1734) in Alzheimer’s disease (AD) and cognitive deficits in schizophrenia, triggering a $20 million milestone payment to Targacept, Inc. This decision follows the completion of previously disclosed studies of AZD3480 (TC-1734) by AZ. “AZ is committed to developing innovative therapies in the areas of unmet need of AD, schizophrenia and other cognitive disorders. Our decision to continue clinical development of AZD348...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters